SEARCH

SEARCH BY CITATION

References

  • BREIVOGEL, C.S., GRIFFIN, G., DI MARZO, V. & MARTIN, B.R. (2001). Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol. Pharmacol., 60, 155163.
  • CHENG, Y.-C. & PRUSOFF, W.H. (1973). Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 percent inhibition (IC50) of an enzymatic reaction. Biochem. Pharmacol., 22, 30993108.
  • DEVANE, W.A., HANUS, L., BREUER, A., PERTWEE, R.G., STEVENSON, L.A., GRIFFIN, G., GIBSON, D., MANDELBAUM, A., ETINGER, A. & MECHOULAM, R. (1992). Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 258, 19461949.
  • ELSOHLY, M.A. (2002). Chemical constituents of Cannabis. In: Cannabis and Cannabinoids. Pharmacology, Toxicology and Therapeutic Potential, ed. Grotenhermen, F. & Russo, E. pp. 2736. New York: Haworth Press, Inc.
  • GILL, E.W., PATON, W.D.M. & PERTWEE, R.G. (1970). Preliminary experiments on the chemistry and pharmacology of cannabis. Nature, 228, 134136.
  • GRIFFIN, G., WRAY, E.J., TAO, Q., MCALLISTER, S.D., RORRER, W.K., AUNG, M.M., MARTIN, B.R. & ABOOD, M.E. (1999). Evaluation of the cannabinoid CB2 receptor-selective antagonist, SR144528: further evidence for cannabinoid CB2 receptor absence in the rat central nervous system. Eur. J. Pharmacol., 377, 117125.
  • HÁJOS, N. & FREUND, T.F. (2002). Pharmacological separation of cannabinoid sensitive receptors on hippocampal excitatory and inhibitory fibers. Neuropharmacology, 43, 503510.
  • HOWLETT, A.C., BARTH, F., BONNER, T.I., CABRAL, G., CASELLAS, P., DEVANE, W.A., FELDER, C.C., HERKENHAM, M., MACKIE, K., MARTIN, B.R., MECHOULAM, R. & PERTWEE, R.G. (2002). International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 54, 161202.
  • KURKINEN, K.M.A., KOISTINAHO, J. & LAITINEN, J.T. (1997). [γ-35S]GTP autoradiography allows region-specific detection of muscarinic receptor-dependent G-protein activation in the chick optic tectum. Brain Res., 769, 2128.
  • MACLENNAN, S.J., REYNEN, P.H., KWAN, J. & BONHAUS, D.W. (1998). Evidence for inverse agonism of SR141716A at human recombinant cannabinoid CB1 and CB2 receptors. Br. J. Pharmacol., 124, 619622.
  • MANG, C.F., ERBELDING, D. & KILBINGER, H. (2001). Differential effects of anandamide on acetylcholine release in the guinea-pig ileum mediated via vanilloid and non-CB1 cannabinoid receptors. Br. J. Pharmacol., 134, 161167.
  • MERKUS, F.W.H.M. (1971). Cannabivarin and tetrahydrocannabivarin, two new constituents of hashish. Nature, 232, 579580.
  • MOLDERINGS, G.J., BÖNISCH, H., HAMMERMANN, R., GÖTHERT, M. & BRÜSS, M. (2002). Noradrenaline release-inhibiting receptors on PC12 cells devoid of α2- and CB1 receptors: similarities to presynaptic imidazoline and edg receptors. Neurochem. Int., 40, 157167.
  • PERTWEE, R., GRIFFIN, G., FERNANDO, S., LI, X., HILL, A. & MAKRIYANNIS, A. (1995a). AM630, a competitive cannabinoid receptor antagonist. Life Sci., 56, 19491955.
  • PERTWEE, R.G. (1997). Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther., 74, 129180.
  • PERTWEE, R.G. (2005a). Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci., 76, 13071324.
  • PERTWEE, R.G. (2005b). Pharmacological actions of cannabinoids. In: Cannabinoids, Handbook of Experimental Pharmacology, ed. Pertwee, R.G., Vol. 168, pp. 151. Heidelburg: Springer-Verlag.
  • PERTWEE, R.G., FERNANDO, S.R., GRIFFIN, G., RYAN, W., RAZDAN, R.K., COMPTON, D.R. & MARTIN, B.R. (1996). Agonist–antagonist characterization of 6′-cyanohex-2′-yne-Δ8-tetrahydrocannabinol in two isolated tissue preparations. Eur. J. Pharmacol., 315, 195201.
  • PERTWEE, R.G., GRIFFIN, G., LAINTON, J.A.H. & HUFFMAN, J.W. (1995b). Pharmacological characterization of three novel cannabinoid receptor agonists in the mouse isolated vas deferens. Eur. J. Pharmacol., 284, 241247.
  • PERTWEE, R.G., ROSS, R.A., CRAIB, S.J. & THOMAS, A. (2002). (−)-Cannabidiol antagonizes cannabinoid receptor agonists and noradrenaline in the mouse vas deferens. Eur. J. Pharmacol., 456, 99106.
  • PERTWEE, R.G., STEVENSON, L.A., ROSS, R.A., PRICE, M.R., WEASE, K.N. & THOMAS, A. (2004). The phytocannabinoid, THCV, potently antagonizes WIN55212-2 and anandamide in the mouse isolated vas deferens. Proc. Br. Pharmacol. Soc., at http://www.pa2online.org/abstractindex.html.
  • PERTWEE, R.G., THOMAS, A., STEVENSON, L.A., MAOR, Y. & MECHOULAM, R. (2005). (−)-7-Hydroxy-4′-dimethylheptyl-cannabidiol activates a non-CB1, non-CB2, non-TRPV1 target in the mouse vas deferens in a cannabidiol-sensitive manner. Neuropharmacology, 48, 11391146.
  • RAZDAN, R.K. (1986). Structure–activity relationships in cannabinoids. Pharmacol. Rev., 38, 75149.
  • RINALDI-CARMONA, M., BARTH, F., MILLAN, J., DEROCQ, J.-M., CASELLAS, P., CONGY, C., OUSTRIC, D., SARRAN, M., BOUABOULA, M., CALANDRA, B., PORTIER, M., SHIRE, D., BRELIÈRE, J.-C. & LE FUR, G. (1998). SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther., 284, 644650.
  • ROSS, R.A., BROCKIE, H.C., STEVENSON, L.A., MURPHY, V.L., TEMPLETON, F., MAKRIYANNIS, A. & PERTWEE, R.G. (1999a). Agonist–inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630. Br. J. Pharmacol., 126, 665672.
  • ROSS, R.A., GIBSON, T.M., BROCKIE, H.C., LESLIE, M., PASHMI, G., CRAIB, S.J., DI MARZO, V. & PERTWEE, R.G. (2001). Structure–activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Br. J. Pharmacol., 132, 631640.
  • ROSS, R.A., GIBSON, T.M., STEVENSON, L.A., SAHA, B., CROCKER, P., RAZDAN, R.K. & PERTWEE, R.G. (1999b). Structural determinants of the partial agonist–inverse agonist properties of 6′-azidohex-2′-yne-Δ8-tetrahydrocannabinol at cannabinoid receptors. Br. J. Pharmacol., 128, 735743.
  • SCHLICKER, E. & KATHMAN, M. (2001). Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci., 22, 565572.
  • SCHLICKER, E., REDMER, A., WERNER, A. & KATHMAN, M. (2003). Lack of CB1 receptors increases noradrenaline release in vas deferens without affecting atrial noradrenaline release or cortical acetylcholine release. Br. J. Pharmacol., 140, 323328.
  • THOMAS, A., ROSS, R.A., SAHA, B., MAHADEVAN, A., RAZDAN, R.K. & PERTWEE, R.G. (2004). 6″-Azidohex-2″-yne-cannabidiol: a potential neutral, competitive cannabinoid CB1 receptor antagonist. Eur. J. Pharmacol., 487, 213221.
  • TRENDELENBURG, A.U., COX, S.L., SCHELB, V., KLEBROFF, W., KHAIRALLAH, L. & STARKE, K. (2000). Modulation of 3H-noradrenaline release by presynaptic opioid, cannabinoid and bradykinin receptors and β-adrenoceptors in mouse tissues. Br. J. Pharmacol., 130, 321330.
  • VON KÜGELGEN, I. & STARKE, K. (1991). Noradrenaline-ATP co-transmission in the sympathetic nervous system. Trends Pharmacol. Sci., 12, 319324.
  • ZYGMUNT, P.M., ANDERSSON, D.A. & HÖGESTÄTT, E.D. (2002). Δ9-tetrahydrocannabinol and cannabinol activate capsaicin-sensitive sensory nerves via a CB1 and CB2 cannabinoid receptor-independent mechanism. J. Neurosci., 22, 47204727.